A3309 is a minimally absorbed ileal bile acid (BA) transporter (IBAT) inhibitor. We conducted an 8-week, multicenter, randomized, double-blind, placebo-controlled, parallel group, phase IIb study, which evaluated A3309 in patients with chronic idiopathic constipation (CIC).
INTRODUCTION
Chronic idiopathic constipation (CIC) is a common gastrointestinal (GI) condition that aff ects quality of life and health-care expenditures ( 1 ) . It has been estimated that 12 -19 % ( 2 ) of the general population experiences CIC. Constipation is more oft en reported by females and those over 65 years of age ( 2 ) . Th e symptoms of CIC are diverse and include infrequent bowel movements (BMs), hard stools, excessive straining, bloating, and abdominal discomfort / pain ( 3 ) . Th ough a number of over-the-counter and prescription medications are available, approximately half of patients with CIC are not satisfi ed with their current treatment ( 4 ) . As such, there remains an unmet need for medical therapies and approaches addressing novel physiological mechanisms in patients with CIC.
Th e pathophysiology of CIC remains incompletely defi ned. Th ere is evidence to suggest that modulation of endogenous bile acid (BA) homeostasis might off er a novel therapeutic approach to the treatment of CIC. Th ere are several examples demonstrating that changes in intracolonic BA concentrations alter bowel function: ileal resection results in diarrhea ( 5 ) , and changes in diurnal rates of BA synthesis and colonic BA concentration have been identifi ed in constipated children ( 6 ) and in adults with slow A Randomized Placebo-Controlled Phase IIb Trial of A3309, A Bile Acid Transporter Inhibitor, for Chronic Idiopathic Constipation transit constipation and constipation-predominant irritable bowel syndrome (IBS-C) ( 7, 8 ) . Conversely, decreasing free BA concentrations in the colon through the use of the BA sequestrant cholestyramine induces constipation ( 5 ) , and another BA sequestrant, colesevelam, retards accelerated colonic transit in patients with IBS-D ( 9 ) .
Inhibitors of the ileal BA transporter (IBAT; syn ASBTapical sodium-dependent BA transporter) reduce the active ileal reabsorption of BA, resulting in an increased concentration of BA entering the colon, thereby stimulating colonic motility and secretion ( 10 ) . BAs induce propulsive contractions in the human colon ( 11 ) , secretion through activation of adenylate cyclase ( 12 ) , increased mucosal permeability ( 13 ) , and inhibition of apical Cl − / OH − exchange ( 14 ) . Th ese eff ects on colonic motility and secretion may off er clinical benefi ts in patients with CIC. A3309 is a selective inhibitor of the IBAT, which has been shown to reduce meat-induced constipation in the dog ( 15 ) . In humans, A3309 accelerated colonic transit in a multiple ascending dose, phase Ib study in patients with CIC ( 16 ) .
Th e current phase IIb study in patients with CIC was performed to assess the short-term effi cacy and safety of orally administered A3309 at 5, 10, and 15 mg doses, compared with placebo, once daily for 8 weeks.
METHODS

Study design: randomization and protocol
A randomized, double-blind, placebo-controlled study was conducted at 45 sites across the United States between November 2009 (fi rst signed informed consent) and August 2010 (last patient visit). Th e study was conducted in accordance with the Declaration of Helsinki and with Good Clinical Practice guidelines. Written informed consent was obtained from all patients before participation. Central or local Ethical Review Boards approved the study protocol and the informed consent form. Th e study was registered on ClinicalTrial.Gov [NCT01007123] . Treatment allocation and concealment were conducted by a computerized random-number generator and numbered containers with active and placebo capsules of identical appearance. Th e randomization list was centrally held by an independent Contract Research Organization, all randomized patients and study center and contract research organization personnel were blinded to study treatment allocation until data were locked and analyzed.
Aft er informed consent was obtained, patients entered an initial screening period of up to 28 days during which routine blood tests, urinalysis, and pregnancy testing were obtained. Where appropriate, patients were taken off of laxatives and other prohibited medications. Specifi c washout periods (3-or 10-day periods based on duration of action) were used for prohibited medications. Bulking agents and stool soft eners were allowed if the patient was taking a stable dose for at least 30 days before the start of the screening period. Th e use of rescue medication (bisacodyl suppository) was permitted following consultation with the investigator if the patient had > 72 h without a BM. Patients meeting the inclusion and exclusion criteria entered a 14-day pretreatment baseline period. Patients eligible to continue were randomized to receive a 5-, 10-, or 15-mg tablet of A3309 or placebo orally once daily before breakfast for 8 weeks. During the 14 days before randomization and during the treatment period, patients reported daily bowel and abdominal symptoms using an Interactive Voice Response System. Study visits occurred during the screening period, at randomization (day 0), during treatment (day 28), at end of treatment (day 56), and 14 days post-treatment (day 70).
Study medication
Pharmacokinetic studies show that orally administered A3309 leads to minimal systemic exposure and that systemically available drug is highly protein bound ( > 99 % ) ( 15 ) .
Study participants
Eligible patients were men or non-pregnant women, 20 -80 years of age, who met modifi ed Rome III criteria for functional constipation ( 17 ) , with a diagnosis of > 3 months and with symptom onset at least 6 months before diagnosis. Study participants were required to have a baseline BM frequency of < 3 complete spontaneous BMs (CSBMs) per week. In addition, ≥ 2 of the following characteristics that are included in the Rome III criteria for functional constipation were required during the 14 days before randomization: (1) straining during ≥ 25 % of BMs, (2) sensation of incomplete evacuation in ≥ 25 % of BMs, (3) lumpy or hard stools in ≥ 25 % of BMs, or (4) sensation of blockage / anorectal obstruction in ≥ 25 % of BMs. Eligible patients had a body mass index of > 18.0 and < 35 kg / m 2 . Patients were excluded if they had been previously diagnosed with constipation-predominant IBS, had abdominal pain as a predominant symptom, or had drug-induced constipation. Also, patients were excluded if they reported the need for manual maneuvers (digital insertion into the rectum, perianal pressure, or vaginal splinting) or frequent use of enemas to evacuate stool. Other exclusion criteria included known rectal prolapse, dyssynergic defecation (per patient history and clinical examination), previous intestinal resection, neurological cause of constipation, and use of drugs with known eff ects on GI motility or stool consistency. Patients reporting loose or liquid stool consistency by a Bristol Stool Form Scale score of 6 or 7 (unless within 24 h of having taken a laxative) at least once during the screening period were excluded ( 18 ) . Patients with persistent constipation symptoms despite a stable dosage of bulking agents for > 4 weeks were eligible.
All study participants were required to meet the colorectal cancer screening requirements of the American Gastroenterological Association Guidelines ( 19 ) . Women of child-bearing age were required to have a negative serum pregnancy test; those who were sexually active were required to use an accepted form of birth control during their participation in the study.
Outcome measures and assessments
Th e primary end point of the study was the change from baseline in frequency of weekly spontaneous bowel movements (SBMs) at week 1. Secondary effi cacy end points included weekly assessment of SBMs and CSBMs, daily assessments of other bowel-related complaints (i.e., stool consistency and straining), and abdominal symptoms (i.e., pain, discomfort, and bloating). Th e time to onset of clinical effi cacy was evaluated by " time to fi rst SBM " and " percentage of patients having an SBM within 24 h of fi rst administration of study drug. " Similar assessments for CSBM were also performed. In addition, we chose to look at the stool frequency responder end point included in a recent US Food and Drug Administration guidance document ( 20 ) ; " CSBM stool frequency responder " was defi ned as a patient who had an increase of ≥ 1 CSBM per week over baseline for at least 4 of the 8 weeks of the treatment period.
Daily symptom assessments
Assessments were recorded by phone using Interactive Voice Response System. Each day, patients recorded the time study medication was taken and the number and time of each BM. Th e characteristics of each BM were assessed using the 7-point Bristol Stool Form Scale ( 18 ) . Th e severity of straining was graded using a 5-point ordinal scale (1 = not at all, 2 = a little bit, 3 = more straining than not, 4 = a great deal, and 5 = an extreme amount). SBM was defi ned as a BM in which no laxative, enema, or suppository was used in the preceding 24 h, and a CSBM was defi ned as an SBM, which was associated with a feeling of complete bowel emptying. Each day, patients also recorded the severity of bloating, pain, and discomfort using 5-point scales (1 = none, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe) and any use of rescue medication.
Surrogate markers of hepatic synthesis and GI loss of BAs
Mechanistic eff ects of A3309 on hepatic BA synthesis rates were evaluated using plasma C4 (7 α -hydroxy-4-cholesten-3-one) ( 21 ) and on plasma lipids (total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides) using a high-performance liquid chromatography method.
Safety assessment
Th e intensity of adverse events (AEs) was reported by patients as mild, moderate, or severe. Separate from AE intensity, patients were defi ned as suff ering from a serious AE (SAE) if the AE resulted in death, was deemed life threatening, led to long-term disability, or required or prolonged hospitalization for treatment. Th e site investigator assessed all patient-reported AEs and determined their relationship to study treatment. Safety evaluations included physical examinations, electrocardiogram, vital signs measurements, and standard laboratory tests (clinical chemistry, hematology, fat-soluble vitamins [A, D, E], and coagulation).
Statistical methods and data analysis
Patients were randomized in a 1:1:1:1 ratio to the treatment groups. Th e sample size for this study was selected to provide 80 % power to detect a diff erence of 2.5 SBMs per week between an active treatment group and the placebo group using a two-sided t -test at α = 0.05 signifi cance without adjustment for multiplicity. Th is calculation was based on the assumption that treatment groups have unequal variances (estimated active s.d. = 4.7, estimated placebo s.d. = 2.6). Th irty-eight patients per treatment group were required to achieve the desired power under the stated assumptions. To allow for a withdrawal rate of 15 % , 45 patients per group (180 patients total) were required.
All changes from baseline end points were analyzed with a one-way analysis of covariance, with a fi xed eff ect for treatment group and the baseline value of SBMs used as a covariate. Within the analysis of covariance, each dose of A3309 was compared with placebo in a pairwise manner. Th e time to the fi rst SBM and the fi rst CSBM were analyzed using a one-way analysis of variance, with a fi xed eff ect for treatment group. Th e binary response end point " CSBM stool frequency responder " was analyzed with Fisher ' s exact test comparing each A3309 dose with placebo.
An observed-cases approach to missing data was applied (i.e., a patient ' s missing values were not imputed or carried forward). All P values are based on two-sided tests and given that this was a phase IIb dose-range fi nding study, the reported P values were not adjusted for multiple comparisons. Patients discontinuing treatment were defi ned as treatment failures for the responder analyses.
Effi cacy analyses are reported for the ITT (intent to treat) population defi ned as all randomized patients who received at least one dose of study medication and had any post-baseline patient diary data (BM or GI symptoms) collected ( n = 190).
Evaluations of serum C4 and lipids, which refl ect pharmacodynamic eff ects of A3309, were performed on the completer per protocol population ( n = 121) defi ned as all ITT patients who completed the study and were at least 80 % compliant with study medication and patient reports during the treatment period.
Safety results are reported for the safety population ( n = 189) defi ned as all randomized patients who received at least one dose of study treatment and for whom follow-up safety data are available. Assessments of safety were performed evaluating number / proportions of patients experiencing SAEs / AEs and with an analysis of any changes from baseline in laboratory safety tests, electrocardiogram, and vital signs.
RESULTS
Patient fl ow and follow-up
Of 448 CIC patients screened, 190 were randomized and 161 completed the study ( Figure 1 ). At baseline, the demographic parameters were similar between the treatment groups ( Table 1 ) . Patients had a mean age of 48.1 years (range 20 -79), and were predominantly female (90 % ) and white (78 % ). Th e mean number of SBMs and CSBMs per week at screening was 2.82 and 0.40, respectively. Full baseline characteristics of our study population can be found in Supplementary Appendix Table 1 online.
Bowel function
Stool frequency . At week 1 of the double-blind treatment phase (primary effi cacy end point), patients treated with 10 or 15 mg of A3309 reported a signifi cantly ( P < 0.002 and P < 0.001, respectively) greater change from baseline in the number of SBMs compared with placebo; Figure 2 shows a clear dose -response with mean (95 % confi dence interval) increases of 2.5 (1.5 -3.5, NS),
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Chey et al. 4 .0 (2.9 -5.0, P < 0.002), and 5.4 (4.4 -6.4; P < 0.001) SBMs for the A3309 dose levels of 5, 10, and 15 mg, compared with an increase of 1.7 (0.7 -2.8) SBMs for placebo. Th e benefi cial eff ect of A3309 on weekly SBM ( Figure 3a ) and CSBM ( Figure 3b ) frequency was maintained over placebo for the 8-week treatment period.
A3309 at doses of 10 and 15 mg signifi cantly reduced the time to fi rst SBM relative to placebo ( P = 0.033 and 0.039, respectively); an SBM occurred (mean) 12 and 7 h aft er fi rst dose of A3309 10 and 15 mg, respectively, compared with (mean) 27 h for placebo. A signifi cantly higher proportion of patients reported an SBM within 24 h of taking their fi rst dose of A3309 at a dose of 10 (74 % ) or 15 mg (75 % ) compared with placebo (45 % ) ( P = 0.012 for both). When considering time to fi rst CSBM or the proportion who reported a CSBM within 24 h of dosing, signifi cant diff erences were again observed with the two higher doses of A3309 compared with placebo ( P ≤ 0.02 for all comparisons).
CSBM stool frequency responder rates were also signifi cantly improved with all three A3309 dose levels compared with placebo; 58 % (25 / 43), 64 % (27 / 42), 75 % (30 / 40) for the 5, 10, and 15 mg groups compared with placebo (33 % , 14 / 42) ( P = 0.030, 0.008, < 0.001, respectively).
Stool consistency and straining . Patients treated with 10 and 15 mg doses of A3309 reported signifi cant improvements in stool consistency and signifi cant decreases in straining at all treatment weeks ( P < 0.001 for all comparisons) ( Figure 4a and b ) .
Abdominal symptoms
Bloating, pain, and discomfort . Th e mean change from baseline in overall bloating across the 8-week treatment period improved in patients receiving the 15-mg dose of A3309 ( P = 0.048) ( Figure  4c ). Th ere were no diff erences in eff ects on abdominal pain or discomfort between the A3309 groups and placebo.
Rescue medication use
Th ere were no signifi cant diff erences in the use of rescue medication between active treatment groups and placebo at any of the study intervals.
Surrogate markers of hepatic BA synthesis and GI loss
Plasma C4 increased in all of the active A3309 dose levels with mean ( ± s.e.m.) changes from baseline being 1.2 ( ± 4.2) for placebo, 14.9 ( ± 4.0) for the 5-mg group, 21.1 ( ± 4.4) for the 10-mg group, 
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Safety assessment
AEs were reported in 102 of the 189 patients (54 % ); 14 patients (7 % ) had events of severe intensity. Th e main diff erence between the groups was that fi ve patients in the 15-mg A3309 group had abdominal cramping / pain and / or diarrhea of severe intensity. Treatment-emergent SEs occurred in 44, 46, 62, and 65 % in the placebo, 5, 10, 15 mg A3309 groups, respectively. Th e most common AEs were of GI origin including abdominal pain (0, 10, 11, and 27 % ) and diarrhea (2, 8, 6 , and 13 % ). In total, 29 patients (15 % ) discontinued study medication (placebo: 12.8 % , 5 mg A3309: 12.5 % , 10 mg A3309: 12.8 % , and 15 mg A3309: 22.9 % ). Table 3 outlines the treatment-emergent AEs and discontinuations during the study. Th e rate of AEs and discontinuations was greater in the 15-mg A3309 group compared with the 5-or 10-mg A3309 or placebo groups. Discontinuations due to GI AEs are outlined in Table 3 .
Th ree SAEs were reported, one in the placebo group (shoulder pain), one in the 5-mg A3309 group (colonoscopy verifi ed bleeding colonic diverticulum 2 weeks aft er the end of treatment), and one in the 10-mg A3309 group (breast carcinoma diagnosed on day 5 of treatment). None of the SAEs were considered related to the study drug. No deaths occurred during the study.
Th ere were no diff erences in the incidence of clinically significant changes in laboratory parameters, vital signs, or other safety parameters. and 12.9 ( ± 5.1) for the 15-mg group ( P = 0.020, 0.002, and 0.082, respectively). Baseline total cholesterol levels were > 200 mg / dl in 43 % of the patients; the mean ( ± s.e.m.) baseline total plasma cholesterol level was 195 ( ± 5.2) mg / dl (ITT population). Signifi cant decreases in total cholesterol were observed for the 10-and 15-mg dose levels ( P = 0.014 and P = 0.027, respectively). Compared with baseline, LDL cholesterol and the LDL / HDL ratio each decreased while on treatment with A3309 ( Table 2 ). Neither A3309 nor 
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The ASBT / IBAT Inhibitor A3309 in Constipation ments in other constipation-associated symptoms (stool consistency, straining, and bloating). Th ere was also benefi t for the rigorous CSBM stool frequency responder defi nition (an increase of ≥ 1 CSBM per week over baseline for at least 4 of the 8 weeks of the treatment period), with all doses of A3309 compared with placebo. Th e eff ects of A3309 on the frequency and consistency of BMs occurred within the fi rst week of drug administration and were maintained over the full 8 weeks of treatment. Roughly three quarters of the patients in the 10-and 15-mg A3309 groups reported passing an SBM within 24 h of initial drug dosing. Importantly, there was no diminution of the clinical benefi ts of A3309 over time, suggesting that there was no development of tolerance. It has long been known that BAs are physiological promoters of colonic secretion and motility ( 10 ) . Reduced synthesis and / or colonic concentrations of specifi c BAs have been associated with the development of constipation ( 6 -8 ) . Th erefore, recent work has investigated the potential role of raising colonic BA concentration (by direct supplementation or through prevention of ileal reabsorption) as a novel target for new drug development in patients with CIC ( 8, 16 ) . BAs are mainly absorbed in the ileum by a specifi c BA transporter or IBAT. Th e IBAT is an integral brush border membrane glycoprotein that co-transports sodium and BAs. Available evidence suggests that the IBAT is a major regulator of the BA pool in animals and humans. BA reabsorption from the intestine is very effi cient; 95 % of the secreted BAs are reabsorbed and delivered back to the liver completing the process of enterohepatic circulation ( 22 ) .
IBAT inhibitors prevent the reabsorption of BAs from the ileum and consequently, their return to the liver. Th e liver compensates
DISCUSSION
Th is randomized, placebo-controlled trial evaluated the effi cacy and safety of three doses of the novel IBAT inhibitor, A3309 in patients with CIC. Compared with placebo, A3309 signifi cantly increased SBMs during week 1 (the primary end point) and each subsequent week of the 8-week treatment period. A3309 also signifi cantly increased weekly CSBMs, an end point that includes the patient ' s qualitative assessment of completeness of a bowel movement and arguably provides an even more rigorous assessment of stool frequency than SBM. A3309 led to signifi cant improve- Completer PP (per protocol) population (all ITT patients who completed the study and were at least 80% compliant with study medication and patient reports during the treatment period). *** P < 0.001, ** P =0.01,* P < 0.05. 
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for the decrease in BAs by upregulating cholesterol 7 α -hydroxylase, the rate-limiting enzyme for BA synthesis. Th is results in increased levels of 7 α -hydroxy-4-cholesten-3-one (C4), an intermediate in BA synthesis. In addition, lower hepatic cholesterol levels and increased number of LDL receptors in the liver occur leading to reduced plasma LDL cholesterol ( 23, 24 ) . Th ese concepts were confi rmed in our study where A3309 but not placebo resulted in increased C4 values and decreased plasma total and LDL cholesterol levels, consistent with increased BA synthesis due to inhibition of IBAT. A3309 ' s cholesterol-lowering eff ect may be an incremental attribute of this treatment that may prove useful in patients with CIC. Th e improvements to constipation symptoms observed with A3309 are likely the consequence of increased delivery of BAs to the colon leading to increased fl uid secretion and motility and resultant acceleration of transit. Th is suggestion is supported by a recent single center, randomized, double-blind dose escalation study in 30 patients with CIC, which found that A3309 significantly accelerated colon transit measured by radio-opaque markers and increased stool frequency compared with placebo ( 16 ) .
Contrary to the clear benefi t of A3309 for constipation-associated symptoms, there was no statistically signifi cant diff erence in abdominal pain or discomfort ratings between the A3309 and placebo groups. Th e interpretation of these fi ndings may be confounded by low baseline scores for abdominal pain and discomfort (fl oor eff ect) likely resulting from the exclusion of patients with a prior history of IBS or abdominal pain or discomfort as a predominant complaint. Further evaluation of A3309 in patients with IBS-C should be considered to more defi nitively evaluate the impact of this drug on abdominal pain and abdominal discomfort.
A3309 was generally well tolerated and no SAEs related to the study drug were reported. Th ere was a dose-related trend in the number of AEs and in the percentage of patients discontinuing treatment. Because A3309 has a very low systemic exposure (resulting in estimated plasma concentrations in the picomolar range), it is reasonable to speculate that AEs, which were largely GI in origin, were the consequence of the increased concentration of colonic BAs ( 11, 25 ) .
Based upon data from this phase IIb dose-range study, it appears that the 10-mg dose of A3309 provided the best balance of effi cacy and safety in patients with CIC. Patients on the 15-mg dose level had more AEs of abdominal pain and diarrhea. It is conceivable that this may refl ect a direct eff ect of the higher dose of A3309 on motility, rather than a secondary eff ect on transit arising from increased colonic secretion. Concentrations of > 5 m M of BAs infused directly into the human rectum and sigmoid stimulate colonic phasic contractions ( 11 ); in addition, Bampton et al. ( 26 ) observed HAPCs in the colon with administration of 1 m M chenodexoycholate into the rectum of healthy volunteers. Such concentrations of 1 -5 m M BAs are seldom achieved in the absence of ileal resection ( 27 ) .
Despite the chronic nature of CIC, many patients use medical therapy intermittently; the speed of onset of A3309 is also potentially benefi cial as it signifi cantly shortened the time to fi rst SBM and CSBM. Treatment with A3309 may therefore be suited for individualized treatment, either on a fi xed schedule or " on demand. "
Further studies specifi cally designed to address these potential uses for A3309 in CIC patients are eagerly awaited.
Forty-three percent of CIC patients enrolled in this study had baseline total plasma cholesterol values above the desirable cutoff level of 200 mg / dl. A3309 treatment induced a decrease in LDL cholesterol and in the important predictor of cardiovascular disease -the LDL / HDL ratio -(14 % decreases in the 10-mg dose group for both variables). Th e benefi cial eff ects on lipid profi le are a unique feature of A3309 among current medications and those in the pipeline for treatment of CIC. Th is improvement in serum lipids might provide incremental benefi ts to a subset of patients with CIC.
When considering our results, several additional issues merit discussion. As is common in drug trials of this size, a large number of investigative sites were included and patient-reported outcomes were captured using an Interactive Voice Response System or with electronic handheld devices. Studies that rely upon electronic data capture might bias the randomized population toward a younger, more affl uent demographic. What eff ect, if any, this could have on our results is unknown. Patients with CIC entered into this study were required to be passing fewer than 3 CSBMs per week. Th is may limit the generalizability of our data to the entire population of CIC patients. Acknowledging this point, the decision for this entry requirement was largely predicated upon current regulatory recommendations, which support stool frequency as the primary outcome for trials evaluating therapies for CIC. Further, though weekly CSBM rate was used to determine study eligibility, weekly SBM rate aft er the fi rst week of therapy served as the primary outcome measure. Th is primary outcome was chosen aft er consultation with the US Food and Drug Administration. In addition to meeting the primary outcome, the two higher doses of A3309 provided robust and signifi cant benefi ts to the rate of weekly SBMs and CSBMs for the entire 8-week treatment period. One further point, which merits consideration, is that our study population likely included a subset of patients with dyssynergic defecation. Th e study protocol called for the exclusion of patients with a history of dyssynergic defecation or in whom the history and physical examination was felt to indicate the presence of this type of constipation. We acknowledge that this is an imperfect way of identifying patients with dyssynergic defecation and that the inclusion of such patients could have aff ected the study results. However, we would point out that nearly all other recently performed trials evaluating novel drug therapies for chronic constipation have handled the issue of dyssynergic defecation in a similar manner ( 28, 29 ) . In addition, randomization would be expected to level the eff ect of the inclusion of such patients on results yielded by the study groups. We would also argue that the practice used in this protocol closely mimics clinical practice where diagnostic testing for dyssynergic defecation is typically reserved for patients who have failed multiple laxative therapies as recommended by the American Gastroenterological Association ( 30 ) and the Rome Foundation ( 31 ) .
In conclusion, the results of this placebo-controlled, dose-range, phase IIb study in CIC patients demonstrated that the IBAT inhibitor A3309 signifi cantly improved BM frequency, stool consistency, and constipation symptoms. Th e 10-mg dose of A3309 provided the best balance of effi cacy and safety. Further large clinical trials evaluating the effi cacy of A3309 in patients with CIC and IBS-C are warranted.
